These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
98 related articles for article (PubMed ID: 31196548)
1. Bio-inspired drug-dominated supramolecular nanocomplex based on low molecular weight heparin for progressive tumor therapy. Yu Y; Xu C; Zhen L; Yang S; Zhou J; Yao J Carbohydr Polym; 2019 Sep; 220():30-42. PubMed ID: 31196548 [TBL] [Abstract][Full Text] [Related]
2. Functionalized heparin-protamine based self-assembled nanocomplex for efficient anti-angiogenic therapy. Alam F; Al-Hilal TA; Chung SW; Park J; Mahmud F; Seo D; Kim HS; Lee DS; Byun Y J Control Release; 2015 Jan; 197():180-9. PubMed ID: 25445701 [TBL] [Abstract][Full Text] [Related]
3. Combination chemotherapy of doxorubicin, all-trans retinoic acid and low molecular weight heparin based on self-assembled multi-functional polymeric nanoparticles. Zhang T; Xiong H; Dahmani FZ; Sun L; Li Y; Yao L; Zhou J; Yao J Nanotechnology; 2015 Apr; 26(14):145101. PubMed ID: 25771790 [TBL] [Abstract][Full Text] [Related]
4. High antiangiogenic and low anticoagulant efficacy of orally active low molecular weight heparin derivatives. Park JW; Jeon OC; Kim SK; Al-Hilal TA; Jin SJ; Moon HT; Yang VC; Kim SY; Byun Y J Control Release; 2010 Dec; 148(3):317-26. PubMed ID: 20869408 [TBL] [Abstract][Full Text] [Related]
5. Self-assembled nanocomplex of PEGylated protamine and heparin-suramin conjugate for accumulation at the tumor site. Park J; Hwang SR; Choi JU; Alam F; Byun Y Int J Pharm; 2018 Jan; 535(1-2):38-46. PubMed ID: 29097141 [TBL] [Abstract][Full Text] [Related]
6. A low-molecular-weight heparin-coated doxorubicin-liposome for the prevention of melanoma metastasis. Chen Y; Peng J; Han M; Omar M; Hu D; Ke X; Lu N J Drug Target; 2015 May; 23(4):335-46. PubMed ID: 25541466 [TBL] [Abstract][Full Text] [Related]
7. Reduced graphene oxide nanosheets coated with an anti-angiogenic anticancer low-molecular-weight heparin derivative for delivery of anticancer drugs. Shim G; Kim JY; Han J; Chung SW; Lee S; Byun Y; Oh YK J Control Release; 2014 Sep; 189():80-9. PubMed ID: 24973719 [TBL] [Abstract][Full Text] [Related]
8. Polyproline-type helical-structured low-molecular weight heparin (LMWH)-taurocholate conjugate as a new angiogenesis inhibitor. Lee E; Kim YS; Bae SM; Kim SK; Jin S; Chung SW; Lee M; Moon HT; Jeon OC; Park RW; Kim IS; Byun Y; Kim SY Int J Cancer; 2009 Jun; 124(12):2755-65. PubMed ID: 19243020 [TBL] [Abstract][Full Text] [Related]
9. Polymer-Drug Nanoparticles Combine Doxorubicin Carrier and Heparin Bioactivity Functionalities for Primary and Metastatic Cancer Treatment. Mei L; Liu Y; Xia C; Zhou Y; Zhang Z; He Q Mol Pharm; 2017 Feb; 14(2):513-522. PubMed ID: 28026951 [TBL] [Abstract][Full Text] [Related]
10. Mitochondrial Targeted Doxorubicin-Triphenylphosphonium Delivered by Hyaluronic Acid Modified and pH Responsive Nanocarriers to Breast Tumor: in Vitro and in Vivo Studies. Liu HN; Guo NN; Wang TT; Guo WW; Lin MT; Huang-Fu MY; Vakili MR; Xu WH; Chen JJ; Wei QC; Han M; Lavasanifar A; Gao JQ Mol Pharm; 2018 Mar; 15(3):882-891. PubMed ID: 29357260 [TBL] [Abstract][Full Text] [Related]
11. Development of low molecular weight heparin based nanoparticles for metastatic breast cancer therapy. Sun H; Cao D; Wu H; Liu H; Ke X; Ci T Int J Biol Macromol; 2018 Jun; 112():343-355. PubMed ID: 29409771 [TBL] [Abstract][Full Text] [Related]
12. Intracellular self-disassemble polysaccharide nanoassembly for multi-factors tumor drug resistance modulation of doxorubicin. Xiong H; Ni J; Jiang Z; Tian F; Zhou J; Yao J Biomater Sci; 2018 Aug; 6(9):2527-2540. PubMed ID: 30105340 [TBL] [Abstract][Full Text] [Related]
13. Dendronized nanoconjugates of lysine and folate for treatment of cancer. Jain K; Gupta U; Jain NK Eur J Pharm Biopharm; 2014 Aug; 87(3):500-9. PubMed ID: 24698808 [TBL] [Abstract][Full Text] [Related]
14. Insight into the role of dual-ligand modification in low molecular weight heparin based nanocarrier for targeted delivery of doxorubicin. Du H; Liu M; Yu A; Ji J; Zhai G Int J Pharm; 2017 May; 523(1):427-438. PubMed ID: 28359815 [TBL] [Abstract][Full Text] [Related]
15. Anti-angiogenic activity and antitumor efficacy of amphiphilic twin drug from ursolic acid and low molecular weight heparin. Cheng W; Dahmani FZ; Zhang J; Xiong H; Wu Y; Yin L; Zhou J; Yao J Nanotechnology; 2017 Feb; 28(7):075102. PubMed ID: 28091396 [TBL] [Abstract][Full Text] [Related]
16. Increased tumor uptake of chemotherapeutics and improved chemoresponse by novel non-anticoagulant low molecular weight heparin. Phillips PG; Yalcin M; Cui H; Abdel-Nabi H; Sajjad M; Bernacki R; Veith J; Mousa SA Anticancer Res; 2011 Feb; 31(2):411-9. PubMed ID: 21378319 [TBL] [Abstract][Full Text] [Related]
17. Doxorubicin-loaded amphiphilic polypeptide-based nanoparticles as an efficient drug delivery system for cancer therapy. Lv S; Li M; Tang Z; Song W; Sun H; Liu H; Chen X Acta Biomater; 2013 Dec; 9(12):9330-42. PubMed ID: 23958784 [TBL] [Abstract][Full Text] [Related]
18. Biocompatible cationic pullulan-g-desoxycholic acid-g-PEI micelles used to co-deliver drug and gene for cancer therapy. Chen L; Ji F; Bao Y; Xia J; Guo L; Wang J; Li Y Mater Sci Eng C Mater Biol Appl; 2017 Jan; 70(Pt 1):418-429. PubMed ID: 27770912 [TBL] [Abstract][Full Text] [Related]
19. Angelica sinensis polysaccharide nanoparticles as a targeted drug delivery system for enhanced therapy of liver cancer. Zhang Y; Cui Z; Mei H; Xu J; Zhou T; Cheng F; Wang K Carbohydr Polym; 2019 Sep; 219():143-154. PubMed ID: 31151511 [TBL] [Abstract][Full Text] [Related]
20. Dermatan carriers for neovascular transport targeting, deep tumor penetration and improved therapy. Ranney D; Antich P; Dadey E; Mason R; Kulkarni P; Singh O; Chen H; Constantanescu A; Parkey R J Control Release; 2005 Dec; 109(1-3):222-35. PubMed ID: 16290245 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]